Ojemda
(Tovorafenib)ApprovedSmall molecule
Day One BiopharmaceuticalsOjemda is a small molecule that works as a RAF Inhibitor.[2] It is being used across 8 indications, with its most advanced program in Approved.[1]
Ojemda is one of 197 small molecule programs targeting Glioma. It is currently in Approved.
8
Indications
11
Total Trials
8
Active Trials
196
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Ojemda
Day One BiopharmaceuticalsApproved
Libtayo
RegeneronPhase 3
Imjudo
AstraZenecaPhase 3
Intismeran Autogene
Merck & Co.Phase 3
Fotemustine
RochePhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
BCD-217
BBiocad
Phase 3
Intron a
Merck & Co.Preclinical
Opdualag
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Glioma3 trials
Melanoma2 trials
Low Grade Glioma2 trials
2 more indications
Regulatory
FDA Approval Timeline[4]
Apr 23, 2024
OJEMDA
NDA NDA218033
Apr 23, 2024
OJEMDA
NDA NDA217700
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tovorafenib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Ojemda. U.S. Food & Drug Administration.
- [6]
- [7]